Table 3. Univariate Cox proportional hazard ratios for DFS with respect to clinical parameters and HTRA1 mRNA expression levels.
| Variable | N = 131 | Numberof events | Hazard Ratio (95% CI) | p a |
| HTRA1 expression | ||||
| low | 75 | 37 | 1 | 0.028 |
| high | 56 | 21 | 0.55 (0.32–0.94) | |
| Age | ||||
| <50 | 23 | 11 | 1 | 0.329 |
| >50 | 108 | 47 | 0.72 (0.37–1.39) | |
| Menopausal status | ||||
| Pre-/peri- | 28 | 14 | 1 | 0.200 |
| postmenopausal | 103 | 44 | 0.82 (0.61–1.11) | |
| Lymph node status | ||||
| negative | 52 | 20 | 1 | 0.023 |
| 1–3 lymph nodes | 43 | 20 | 1.22 (0.64–2.27) | |
| 4–9 lymph nodes | 11 | 4 | 1.19 (0.41–3.47) | |
| >9 lymph nodes | 6 | 5 | 4.82 (1.77–13.14) | |
| unknown | 19 | |||
| Tumor stage (pT) | ||||
| 1 | 39 | 16 | 1 | 0.148 |
| 2 | 72 | 31 | 1.18 (0.65–2.17) | |
| 3+4 | 18 | 11 | 2.26 (0.97–4.55) | |
| unknown | 2 | |||
| Nuclear grading | ||||
| 1+2 | 49 | 22 | 1 | 0.489 |
| 3 | 46 | 23 | 1.23 (0.69–2.21) | |
| unknown | 36 | |||
| Estrogen receptor | ||||
| negative | 37 | 17 | 1 | 0.983 |
| positive | 91 | 40 | 1.01 (0.57–1.78) | |
| unknown | 3 | |||
| Progesterone receptor | ||||
| negative | 51 | 21 | 1 | 0.443 |
| positive | 77 | 36 | 1.24 (0.72–2.12) | |
| unknown | 3 | |||
| Adjuvant therapy | ||||
| none | 61 | 25 | 1 | 0.730 |
| endocrine only | 50 | 23 | 1.01 (0.56–1.86) | |
| chemotherapy | 20 | 10 | 1.36 (0.63–2.92) | |
a
Univariate Cox regression analysis; 95% CI, 95% confidence interval; DFS, disease-free survival with endpoints recurrence and/or death.